Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Condition: Non Small Cell Lung Cancer Intervention: Drug: Pyrotinib Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials